CVSI CV Sciences Inc

CV Sciences, Inc. Announces a New Category of Its Industry-Leading PlusCBD Oilâ„¢ Products, Hemp Extract Gummies

CV Sciences, Inc. Announces a New Category of Its Industry-Leading PlusCBD Oil™ Products, Hemp Extract Gummies

LAS VEGAS, Sept. 25, 2018 (GLOBE NEWSWIRE) -- (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) preeminent supplier and manufacturer of hemp-derived phytocannabinoids including industry leading brand, , announced today that it has introduced PlusCBD Oil™ Gummies at the Natural Product Expo East 2018.

A new category of PlusCBD Oil™ products, PlusCBD Oil™ Gummies are offered in two tasty flavors, Cherry Mango and Citrus Punch. A line extension of our Gold Formula line with no artificial ingredients, each gummy contains 5 mg of CBD and a mere 1.5 g of sugar. Gluten free, vegan friendly, and non-GMO, these new products support healthy balance of the body and mind. 

“We are pleased to introduce PlusCBD Oil™ Gummies to our existing line of industry leading hemp extract products that include balms, sprays, drops, capsules, and softgels,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “We are committed to innovation of our PlusCBD Oil™ products, and as the demand for CBD infused products continues to grow, it is important to expand our wide variety of products to suit all customer preferences. We foresee PlusCBD Oil™ Gummies being a solid revenue driving category for our Company.”

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.  Additional information is available from OTCMarkets.com or by visiting

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag

Managing Director

IRTH Communications



866-976-4784

EN
25/09/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CV Sciences Inc

 PRESS RELEASE

CV Sciences, Inc. Reports First Quarter 2022 Financial Results

CV Sciences, Inc. Reports First Quarter 2022 Financial Results SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021;Gross margin of 26.0% for first quarter of 2022, compared to 32.4% for t...

 PRESS RELEASE

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2...

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. The webcast of the conference call will be ...

 PRESS RELEASE

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and Operating Highlights Revenue of $20.0 million for fiscal year 2021, compared to $24.4 million for 2020;Gross margin of 43.0% for fiscal year 2021, compared to 45.1% for 2020;Total cash balance of $1.4 million a...

 PRESS RELEASE

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Result...

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022 SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The ...

 PRESS RELEASE

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line o...

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch